{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-134733","form_type":"8-K","ticker":"MGX","cik":"0001785279","company_name":"Metagenomi Therapeutics, Inc.","filed_at":"2024-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.620604+00:00","generated_at":"2026-05-29T05:14:52.291420+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Metagenomi reports durable FVIII activity >16 mo in NHP hemophilia A study; MGX-001 IND on track for 2026","bullets":["FVIII activity sustained across 13-16.5 months in NHPs: 72%, 9%, 30% at 16.5 mo; integration freq 0.7-3.1%.","MGX-001 bioengineered FVIII showed higher activity vs wild-type at similar integration rates in separate NHP study.","No off-target editing identified to date in orthogonal assays; program targeting IND filing in 2026.","Transient liver transaminase elevation at AAV/LNP dosing; no safety findings on albumin or bilirubin."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-134733","json":"https://secwatch.observer/filing/0000950170-24-134733.json","markdown":"https://secwatch.observer/filing/0000950170-24-134733.md","text":"https://secwatch.observer/filing/0000950170-24-134733.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024134733/0000950170-24-134733-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024134733/mgx-20241209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:14:52.291420+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}